REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
9.03
-0.23 (-2.48%)
Sep 17, 2025, 4:00 PM EDT - Market closed
REGENXBIO Market Cap
REGENXBIO has a market cap or net worth of $456.14 million as of September 18, 2025. Its market cap has decreased by -24.48% in one year.
Market Cap
456.14M
Enterprise Value
364.24M
1-Year Change
-24.48%
Ranking
Category
Stock Price
$9.03
Market Cap Chart
Since September 17, 2015, REGENXBIO's market cap has decreased from $749.30M to $456.14M, a decrease of -39.12%. That is a compound annual growth rate of -4.84%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Sep 17, 2025 | 456.10M | 19.09% |
| Dec 31, 2024 | 383.00M | -51.50% |
| Dec 29, 2023 | 789.70M | -19.57% |
| Dec 30, 2022 | 981.90M | -29.79% |
| Dec 31, 2021 | 1.40B | -17.57% |
| Dec 31, 2020 | 1.70B | 12.32% |
| Dec 31, 2019 | 1.51B | 0.48% |
| Dec 31, 2018 | 1.50B | 45.18% |
| Dec 29, 2017 | 1.04B | 110.87% |
| Dec 30, 2016 | 491.10M | 12.43% |
| Dec 31, 2015 | 436.80M | -41.71% |
| Sep 17, 2015 | 749.30M | - |
View and export this data all the way back to 2015. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 682.40B |
| Johnson & Johnson | 426.76B |
| AbbVie | 390.07B |
| UnitedHealth Group | 309.39B |
| Novo Nordisk | 260.64B |
| AstraZeneca | 241.43B |
| Novartis AG | 237.64B |
| Abbott Laboratories | 233.52B |